Tg Therapeutics is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of various hematologic malignancies and autoimmune diseases
With a strong emphasis on targeted therapies, the company aims to improve patient outcomes through its proprietary drug candidates, which are designed to engage the immune system in a more effective manner. Tg Therapeutics is committed to advancing its research and development efforts to address unmet medical needs in these challenging therapeutic areas, leveraging the latest scientific advancements to enhance patient care.
Uncover the potential of TG THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:TGTX is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation.
Annual revenue from its MS drug, Briumvi, more than tripled, with U.S. net product revenue reaching $103.6 million in the fourth quarter and $310 million for the full year.
